🇺🇸 FDA
Pipeline program

Emixustat

4429-301

Phase 3 small_molecule completed

Quick answer

Emixustat for Stargardt Disease is a Phase 3 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Stargardt Disease
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials